Lauren Feldman 2/17/2023 at 2:20 pm
Nature (February 16, 2023) Mini-organs attract big pharma
Hans Clevers, head of Pharma Research & Early Development at Roche, discusses the role for organoids in drug discovery and development.
Live Science (February 16, 2023) FDA no longer requires animal testing for new drugs. Is that safe?
The U.S. Food and Drug Administration (FDA) no longer requires new drugs to be tested in animals before being approved. Thanks to a law passed in December 2022 (opens in new tab), the agency now has the option to approve drugs that are tested in only non-animal studies, including those that use lab-grown tissues or computer models, before being tested in clinical trials with humans. But is that safe, and will it happen any time soon? For now, no one should expect a dramatic shift in how drug developers bring medicines to market, experts told Live Science.
Fortune (February 15, 2023) 3D-printed organs may soon be a reality. ‘Looking ahead, we’ll not need donor hearts’
From the realm of near-fiction to the germ of an idea to actual science, 3D bioprinting is advancing across all aspects of medical research—and, now, practice. The pace is slow, and target dates for some of the most ambitious 3D plans are decades off. But progress is real.
MIT Technology Review (February 15, 2023) AI is dreaming up drugs that no one has ever seen. Now we’ve got to see if they work.
AI automation throughout the drug development pipeline is opening up the possibility of faster, cheaper pharmaceuticals.
Nature (February 13, 2023) The evolving role of investigative toxicology in the pharmaceutical industry
For decades, preclinical toxicology was essentially a descriptive discipline in which treatment-related effects were carefully reported and used as a basis to calculate safety margins for drug candidates. In recent years, however, technological advances have increasingly enabled researchers to gain insights into toxicity mechanisms, supporting greater understanding of species relevance and translatability to humans, prediction of safety events, mitigation of side effects and development of safety biomarkers. Consequently, investigative (or mechanistic) toxicology has been gaining momentum and is now a key capability in the pharmaceutical industry. This article provides an overview of the current status of the field using case studies and discuss the potential impact of ongoing technological developments, based on a survey of investigative toxicologists from 14 European-based medium-sized to large pharmaceutical companies.
- You must be logged in to reply to this topic.